143 related articles for article (PubMed ID: 36946996)
1. Novel Indole-Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction.
Liu Z; Wang M; Huang R; Hu T; Jing Y; Huang X; Hu W; Cao G; Wang H
J Med Chem; 2023 Apr; 66(7):4868-4887. PubMed ID: 36946996
[TBL] [Abstract][Full Text] [Related]
2. Novel 4-Amino-Quinazoline moieties ligated Platinum(IV) prodrugs overcome cisplatin resistance in EGFR
Li R; Zhao W; Jin C; Xiong H
Bioorg Chem; 2023 Jun; 135():106499. PubMed ID: 37058978
[TBL] [Abstract][Full Text] [Related]
3. Novel Platinum(IV) complexes intervene oxaliplatin resistance in colon cancer via inducing ferroptosis and apoptosis.
Liu Z; Cai J; Jiang G; Wang M; Wu C; Su K; Hu W; Huang Y; Yu C; Huang X; Cao G; Wang H
Eur J Med Chem; 2024 Jan; 263():115968. PubMed ID: 37995563
[TBL] [Abstract][Full Text] [Related]
4. Platinum(IV) Prodrugs with Cancer Stem Cell Inhibitory Effects on Lung Cancer for Overcoming Drug Resistance.
Wang X; Liu Z; Wang Y; Gou S
J Med Chem; 2022 Jun; 65(11):7933-7945. PubMed ID: 35635560
[TBL] [Abstract][Full Text] [Related]
5. Dual-target platinum(IV) complexes reverse cisplatin resistance in triple negative breast via inhibiting poly(ADP-ribose) polymerase (PARP-1) and enhancing DNA damage.
Li R; Zhao W; Jin C; Xiong H
Bioorg Chem; 2023 Apr; 133():106354. PubMed ID: 36720184
[TBL] [Abstract][Full Text] [Related]
6. Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance.
Wang M; Li G; Jiang G; Cai J; Liu Z; Huang R; Huang X; Wang H
J Med Chem; 2024 Apr; 67(8):6218-6237. PubMed ID: 38573870
[TBL] [Abstract][Full Text] [Related]
7. Platinum(IV) complexes conjugated with chalcone analogs as dual targeting anticancer agents: In vitro and in vivo studies.
Huang X; Liu Z; Wang M; Yin X; Wang Y; Dai L; Wang H
Bioorg Chem; 2020 Dec; 105():104430. PubMed ID: 33171407
[TBL] [Abstract][Full Text] [Related]
8. Ligustrazine-Derived Chalcones-Modified Platinum(IV) Complexes Intervene in Cisplatin Resistance in Pancreatic Cancer through Ferroptosis and Apoptosis.
Wang M; Cao G; Zhou J; Cai J; Ma X; Liu Z; Huang X; Wang H
J Med Chem; 2023 Oct; 66(19):13587-13606. PubMed ID: 37766483
[TBL] [Abstract][Full Text] [Related]
9. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
10. Effective platinum(IV) prodrugs conjugated with lonidamine as a functional group working on the mitochondria.
Chen H; Chen F; Hu W; Gou S
J Inorg Biochem; 2018 Mar; 180():119-128. PubMed ID: 29253663
[TBL] [Abstract][Full Text] [Related]
11. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
Liu Z; Wang M; Wang H; Fang L; Gou S
Eur J Med Chem; 2020 May; 194():112269. PubMed ID: 32248002
[TBL] [Abstract][Full Text] [Related]
12. Neferine and isoliensinine enhance 'intracellular uptake of cisplatin' and induce 'ROS-mediated apoptosis' in colorectal cancer cells - A comparative study.
Manogaran P; Beeraka NM; Huang CY; Vijaya Padma V
Food Chem Toxicol; 2019 Oct; 132():110652. PubMed ID: 31255669
[TBL] [Abstract][Full Text] [Related]
13. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H
Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
[TBL] [Abstract][Full Text] [Related]
14. Panduratin A Derivative Protects against Cisplatin-Induced Apoptosis of Renal Proximal Tubular Cells and Kidney Injury in Mice.
Thongnuanjan P; Soodvilai S; Fongsupa S; Thipboonchoo N; Chabang N; Munyoo B; Tuchinda P; Soodvilai S
Molecules; 2021 Nov; 26(21):. PubMed ID: 34771049
[TBL] [Abstract][Full Text] [Related]
15. Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396859
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells.
Horibe S; Ishikawa K; Nakada K; Wake M; Takeda N; Tanaka T; Kawauchi S; Sasaki N; Rikitake Y
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34935060
[TBL] [Abstract][Full Text] [Related]
17. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
Qiao X; Gao YY; Zheng LX; Ding XJ; Xu LW; Hu JJ; Gao WZ; Xu JY
Eur J Med Chem; 2021 Nov; 223():113730. PubMed ID: 34388483
[TBL] [Abstract][Full Text] [Related]
18. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
Wang Z; Xu Z; Zhu G
Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
[TBL] [Abstract][Full Text] [Related]
19. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
Chen H; Wang X; Gou S
J Inorg Biochem; 2019 Apr; 193():133-142. PubMed ID: 30731264
[TBL] [Abstract][Full Text] [Related]
20. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling.
Wang LH; Li Y; Yang SN; Wang FY; Hou Y; Cui W; Chen K; Cao Q; Wang S; Zhang TY; Wang ZZ; Xiao W; Yang JY; Wu CF
Br J Cancer; 2014 Jan; 110(2):341-52. PubMed ID: 24300974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
